We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Endometrial Cancer Lymphadenectomy Trial (ECLAT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03438474
Recruitment Status : Recruiting
First Posted : February 19, 2018
Last Update Posted : May 10, 2023
Sponsor:
Collaborator:
German Cancer Aid
Information provided by (Responsible Party):
Philipps University Marburg Medical Center

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary aim of this trial is to ascertain whether or not systematic pelvic and para-aortic lymphadenectomy (LNE) does have a significant impact on overall survival (OS) in patients with endometrial cancer (EC) FIGO Stages I or II and high risk of recurrence. Secondary aims will be to evaluate the effect of LNE on disease free survival (DFS) and quality of life, as well as the complications and side effects of LNE and the number of resected lymphnodes. 640 patients with histologically confirmed EC with high risk of recurrence (stage pT1b - pT2, all histological subtypes; pT1a, G3 endometrioid or serous or clear cell EC or carcinosarcomas) will be randomized. In Arm A, a total hysterectomy and bilateral salpingo-oophorectomy and in case of serous or clear cell EC additionally an omentectomy will be performed. In arm B in addition a systematic pelvic and para-aortic LNE up to the level of the left renal vein will be performed.

Condition or disease Intervention/treatment Phase
Cancer of Endometrium Stage I Cancer of Endometrium Stage II Procedure: Standard surgical procedure for endometrial cancer Procedure: systematic lymphadenectomy (LNE) Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 640 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pelvic and Para-aortic Lymphadenectomy in Patients With Stage I or II Endometrial Cancer With High Risk of Recurrence
Actual Study Start Date : March 28, 2018
Estimated Primary Completion Date : February 15, 2028
Estimated Study Completion Date : February 15, 2029
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: Arm A standard surgical procedure

Standard surgical procedure for endometrial cancer:

total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

 Procedure: Standard surgical procedure for endometrial cancer
total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)
Experimental: Arm B systematic lymphadenectomy (LNE)

In addition to standard procedures as defined for Arm A:

systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels

 Procedure: Standard surgical procedure for endometrial cancer
total hysterectomy, bilateral salpingo-oophorectomy, omentectomy (type 2 cancers)

Procedure: systematic lymphadenectomy (LNE)
systematic pelvic and para-aortic lymphadenectomy (LNE) up to the renal vessels


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Overall survival (OS) [ Time Frame: 60 months ]
    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on overall survival in EC patients with high risk of recurrence


Secondary Outcome Measures :
  1. Disease free survival (DFS) [ Time Frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months ]
    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease free survival

  2. Disease specific survival (DSS) [ Time Frame: 3 months, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months ]
    Impact of systematic pelvic and para-aortic lymphadenectomy (LNE) on Disease specific survival

  3. Assessment of serious complications [ Time Frame: during surgery, at hospital discharge, day 60, 6 months, 9 months, 12 months ]
    Assessment of perioperative complications and site effects of LNE

  4. EORTC QLQ-C30 [ Time Frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months ]
    Health related Quality of life (QoL)

  5. EORTC QLQ-EN24 [ Time Frame: Baseline, at hospital discharge, 6 months, 9 months, 12 months, 15 months, 18 months, 21 months, 24 months, 27 months, 30 months, 33 months, 36 months, 42 months, 48 months, 54 months, 60 months ]
    Health related Quality of life (QoL)

  6. Number of resected lymph nodes [ Time Frame: during surgery ]
    resected pelvic and para-aortic lymph nodes


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. histologically confirmed EC of clinical stages T1b and T2 (all histological types) and stage T1a G3 type 1 (endometrioid, endometriod with squamous differentiation, mucinous) or type 2 tumors (any percentage of serous or clear cell component) or carcinosarcoma
  2. a) no previous surgery concerning EC (primary surgery) or b) surgery after hysterectomy (e.g. for presumed low risk endometrial cancer) is allowed within 8 weeks after hysterectomy if no LNE was performed (secondary surgery)
  3. absence of bulky lymph nodes
  4. performance status ECOG 0-1
  5. age 18 - 75 years
  6. written informed consent
  7. adequate compliance

Exclusion Criteria:

  1. stage pT1a, G1 or G2 tumors of type 1 histology
  2. sarcomas (except for carcinosarcoma = malignant mixed Müllerian tumor)
  3. EC of FIGO stages III or IV (except for microscopical lymph node metastases)
  4. evidence of extrauterine disease by visual inspection
  5. recurrent EC
  6. preceding chemo-, radio, or endocrine therapy for EC
  7. any concomitant disease not allowing surgery including lymphadenectomy and/or chemotherapy
  8. any medical history indicating excessive peri-operative risk
  9. any current medication containing considerable surgical risk (e.g. bleeding: due to oral anticoagulating agents)
  10. any known disorder or circumstances making participation in trial and follow-up questionable. Insufficient compliance is expected.
  11. patients with second malignancies if disease or treatment might have an impact on the patient's prognosis
  12. known HIV-infection or AIDS
  13. simultaneous participation in other clinical trials if not permitted by the steering committee (translational or QoL studies not interfering with the objectives of ECLAT are allowed)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03438474


Contacts
Layout table for location contacts
Contact: Günter Emons, Professor MD 0049 (0) 551-39 66532 emons@med.uni-goettingen.de
Contact: Philipp Harter, MD 0049 (0) 201 1743-4511 p.harter@kliniken-essen-mitte.de

Locations
Show Show 61 study locations
Sponsors and Collaborators
Philipps University Marburg Medical Center
German Cancer Aid
Investigators
Layout table for investigator information
Principal Investigator: Philipp Harter, MD Kliniken Essen Mitte, Gynäkologie und gynäkologische Onkologie
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Philipps University Marburg Medical Center
ClinicalTrials.gov Identifier: NCT03438474    
Other Study ID Numbers: AGO-OP.6 KKS 228
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: May 10, 2023
Last Verified: May 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
 Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases